Contract Pharma Manufacturing News

  1. Piramal Pharma Solutions Announces Partnership With Botanix To Support Drug Substance Development 5/18/2026

    Piramal Pharma Solutions (PPS), a leading global Contract Development and Manufacturing Organization (CDMO) and part of Piramal Pharma Ltd. (NSE: PPLPHARMA) (BSE: 543635), has entered a manufacturing and supply arrangement with Botanix SB Inc., a subsidiary of Botanix Pharmaceuticals Limited (ABN 70 009 109 755) (ASX:BOT) ("Botanix"), a commercial dermatology company.

  2. Aldevron And Minaris Renew Lentiviral Plasmid Agreement 5/14/2026

    FARGO, N.D. & PHILADELPHIA–(BUSINESS WIRE)–Aldevron, a Danaher company and global leader in the production of DNA, RNA and protein for genomic medicine, and Minaris, a global cell and gene therapy contract development and manufacturing organization (CDMO) and multimodality biosafety testing provider today announced a renewed licensing agreement that expands access to a proprietary, off-the-shelf lentiviral plasmid system for gene-modified cell therapy applications.

  3. Agilent And Veeda Lifesciences Launch Joint Analytical Center Of Excellence To Accelerate GLP 1 And Complex Biologics Development Services 5/13/2026

    Agilent Technologies, a global leader in analytical and laboratory solutions, today announced a strategic collaboration with Veeda Lifesciences to strengthen regulatory‑aligned analytical and bioanalytical workflows supporting biopharma development, as GLP‑1 and other complex therapeutic modalities continue to advance rapidly through global pipelines.

  4. Nuvation Bio To Collaborate With Thermo Fisher Scientific For U.S.-Based Manufacturing Of IBTROZI® For ROS1-Positive Non-Small Cell Lung Cancer 5/13/2026

    Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced the successful completion of process tech transfer and product introduction to Thermo Fisher Scientific, the world leader in serving science, for IBTROZI® (taletrectinib) to treat advanced or metastatic ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC).

  5. Terumo Blood And Cell Technologies And Steminent Collaborate To Advance MSC Late-Stage Clinical Manufacturing 5/13/2026

    Terumo Blood and Cell Technologies (Terumo BCT), a medical technology company and global leader in blood management solutions, and Steminent Biotherapeutics have entered into a strategic collaboration to accelerate late-stage manufacturing readiness for mesenchymal stem cell (MSC) therapies, addressing one of the key barriers to clinical scale-up and commercialization in regenerative medicine.

  6. Piramal Pharma Solutions Unveils State-Of-The-Art Payload-Linker Suite At Its Riverview, Michigan Facility 5/13/2026

    Piramal Pharma Solutions, a leading global Contract Development and Manufacturing Organization (CDMO) and part of Piramal Pharma Ltd.(“PPS”), has officially unveiled a new, state-of-the-art payload-linker development and manufacturing suite at its Riverview, Michigan drug substance facility.

  7. Vector Science & Therapeutics Agrees To An Option To Invest In LyoGenesis Plus, Securing Long-Term Access To FDA-Registered, cGMP Manufacturing 5/13/2026

    Vector Science & Therapeutics (TSXV: PAIN) ("Vector" or the "Company") today announced it has entered into an option agreement to purchase up to a 15% equity interest in LyoGenesis Plus for cash payments over time, from treasury for of up to US$1,000,000 (the "Option").

  8. OrganaBio Acquires Excellos Operating Assets, Establishing A Coast-To-Coast Cell Therapy Contract Testing, Development And Manufacturing Organization 5/13/2026

    OrganaBio, LLC ("OrganaBio"), a manufacturer of GMP cells and blood products and provider of cell isolation and cryopreservation services, has acquired substantially all of the operating assets of San Diego-based Excellos Inc. to create a bicoastal cell therapy contract development and manufacturing organization.

  9. Fosun Pharma And Aribio Sign Exclusive Global Option Agreement For AR1001 For The Treatment Of Alzheimer's Disease 5/13/2026

    On 13 May, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun Pharma"; stock code: 600196.SH, 02196.HK) and AriBio Co., Ltd. ("AriBio"), a biopharmaceutical company focused on neurodegenerative diseases, today jointly announced the signing of an exclusive global option agreement for the development, registration, manufacturing and commercialization of AR1001, an innovative drug candidate for the treatment of Alzheimer's disease (AD).

  10. Andelyn Biosciences Receives Dark Horse Consulting Certification Of Gene Therapy Manufacturing Systems And Capabilities Within Its Initiative For Certification Of Manufacturing Capabilities (ICMC™) Program 5/13/2026

    Andelyn Biosciences, a leading cell and gene therapy Contract Development and Manufacturing Organization (CDMO), today announced it has received full certification under the Initiative for Certification of Manufacturing Capabilities (ICMC) program from Dark Horse Consulting, recognizing the company's capability to support advanced therapies manufacturing with its quality and production systems.